This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. RCMI funds were awarded to accelerate the development of research infrastructure in selected areas of research excellence that focus on improving minority health and eliminating health disparities. RCMI funding will serve as an investment in the development of JABSOM into a research-intensive institution, by supporting the biomedical research career development of 10 promising investigators who will contribute to significantly enlarging the small core of existing researchers at UHM.
The specific aims are to: 1)develop an internationally recognized research program in molecular pharmacology; 2)develop research excellence in immunogenetic diseases; 3)further develop and expand the physical infrastructure and human resources for a comprehensive and multidiciplinary clinical and molecular retrovirology research program; and 4)progressivesly expand the infrastructure and services provided by the Core Support activity to include a strengthened molecular biology core facility to incorporate rapidly emerging technologies, an expanded computer network support facility and a newly developed biostatistics and data management facility. Starting in Year 18 supplemental funding was awarded to develop a HIV vaccine and immunology core activity. The administrative core is responsible for the overall policies and implementation of the RCMI program, convening meetings of the internal and external advisory committees, organizing the monthly RCMI Forum, preparing and submitting the annual reports and other information requested by agency, and coordinating with other NCRR funded programs at the institution.
Showing the most recent 10 out of 347 publications
